Shots: PharmaShots’ Designation Report offers a concise overview of the latest drug and device designations granted by major regulatory authorities, including the FDA, EMA, MHLW, Health Canada, and NMPA. The July 2025 edition covers designations awarded to 47 drugs and 3 medical devices, comprising 23 small molecules, 9 biologics, 8 cell and gene therapies, and…
Shots:Cell and gene therapies provide a promising opportunity to enhance care for unmet healthcare needs. Biopharma companies are actively exploring these therapies across multiple indications to address healthcare gaps in rare and chronic diseasesIn 2023, the cell and gene therapy market was valued at $18.2B and is projected to grow to $117.46B by…
Shots: Betty Woo, VP of Cell, Gene, and Advanced Therapies, Thermo Fisher Scientific discusses the evolution of ThermoFisher’s strategic collaboration with ArsenalBio Betty highlights the development of programmable autologous T cells for the treatment of cancer and the cell therapy collaboration program Betty believes that through innovation and partnership, they can tap into the full…
Shots: PharmaShots' designation report provides a condensed overview of several drugs and their designations by the US FDA, the EU, China, and the UK. This month’s report includes 7 biological drugs, 13 small molecules and 9 cell and gene therapies CellCentric’s Inobrodib, for multiple myeloma and Rocket Pharmaceuticals’ RP-A601, for PKP2-arrhythmogenic cardiomyopathy were the two…

